Zai Lab Limited
ZLABNext catalyst
povetacicept
immunoglobulin A nephropathy (IgAN)
Get an email about ZLAB's next catalysts
Track Zai Lab (ZLAB) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 2 more upcoming events in our data (Phase 3 readout, Phase 2 readout).See the timeline
3 upcoming, 1 past
FDA PDUFA Date povetacicept (accelerated)
For immunoglobulin A nephropathy (IgAN). BLA filing. Extracted from SEC filing: EX-99.1
SourceZL-1109 (VRDN-003) Phase 3 Est. Readout
Primary completion for ZL-1109 (VRDN-003) trial (NCT07211776) in Thyroid Eye Disease (TED)
SourceZL-1310 Phase 2 Est. Readout
Primary completion for ZL-1310 trial (NCT06885281) in Solid Tumors
SourceUpcoming FDA decisions
How ZLAB's past catalysts played out
Market Overview
Stock performance and key metrics
Investigator's Choice of Therapy
Small-cell Lung Cancer
Omadacycline
Community-acquired Bacterial Pneumonia
ZL-1109 (VRDN-003)
Thyroid Eye Disease (TED)
ZL-1310
Solid Tumors
ZL-2306(Niraparib)
Ovarian Cancer
Obrixtamig
Small Cell Lung Cancer
ZL-3101
Eczema
DCC-2618
Gastrointestinal Stromal Tumors
Brivanib
Hepatocellular Carcinoma (HCC)
ZL-1102
Plaque Psoriasis
Ripretinib
Gastrointestinal Stromal Tumor(GIST)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Investigator's Choice of Therapy | Phase 3 | Small-cell Lung Cancer | - | - |
Omadacycline | Phase 3 | Community-acquired Bacterial Pneumonia | - | - |
ZL-1109 (VRDN-003) | Phase 3 | Thyroid Eye Disease (TED) | - | - |
ZL-1310 | Phase 3 | Solid Tumors | - | - |
ZL-2306(Niraparib) | Phase 2 | Ovarian Cancer | - | - |
Obrixtamig | Phase 2 | Small Cell Lung Cancer | - | - |
ZL-3101 | Phase 2 | Eczema | - | - |
DCC-2618 | Phase 2 | Gastrointestinal Stromal Tumors | - | - |
Brivanib | Phase 2 | Hepatocellular Carcinoma (HCC) | - | - |
ZL-1102 | Phase 2 | Plaque Psoriasis | - | - |
Ripretinib | Phase 2 | Gastrointestinal Stromal Tumor(GIST) | - | - |
Frequently asked questions
What is in Zai Lab Limited's drug pipeline?→
CatalystAlert tracks 11 drug candidates in Zai Lab Limited's (ZLAB) pipeline across Phase 3, Phase 2. Its lead program is ZL-1109 (VRDN-003) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Zai Lab Limited's next FDA catalyst?→
Zai Lab Limited's (ZLAB) next tracked catalyst is a PDUFA date expected Nov 30, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ZLAB biotech catalysts?→
Add ZLAB to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Zai Lab Limited's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
